Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Adjusts Merck & Co.'s Price Target to $82 from $88, Keeps Equalweight Rating

11/29/2021 | 10:14am EST


© MT Newswires 2021
All news about MERCK & CO., INC.
09:57aJPMorgan Adjusts Merck's Price Target to $95 From $100, Reiterates Overweight Rating
MT
07:58aEuropean Commission Approves Merck's KEYTRUDA as Adjuvant Therapy for Certain Patients ..
AQ
07:27aMERCK : Molnupiravir Covid-19 Pill Effective Against Omicron in Lab Tests
DJ
07:15aMerck Says Molnupiravir Active Against Omicron Variant in In Vitro Studies
MT
06:46aMerck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine..
BU
01/27Merck & Co.'s Keytruda Wins EU Nod for Adjuvant Treatment of Kidney Cancer
MT
01/27Merck Gets EU Expanded OK for Keytruda in Some Kidney Cancer Patients
DJ
01/27Merck's Keytruda Gets EU Nod for Use as Adjuvant Therapy in Renal Cell Carcinoma
MT
01/27European Commission Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for ..
BU
01/27European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy..
CI
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 434 M - -
Net income 2021 11 938 M - -
Net Debt 2021 17 081 M - -
P/E ratio 2021 17,2x
Yield 2021 3,24%
Capitalization 204 B 204 B -
EV / Sales 2021 4,56x
EV / Sales 2022 3,82x
Nbr of Employees 73 500
Free-Float 70,6%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 80,58 $
Average target price 92,09 $
Spread / Average Target 14,3%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.5.14%203 541
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960